Acknowledgements
SU2C) Colorectal, Gastrointestinal Cancer, Cancer
GASTROINTESTINAL CANCER, CANCER
This work was supported by the NIH/NCI Gastrointestinal Cancer SPORE (P50 CA127003 to A.S. and R.B.C.), the NIH/NCI Moonshot DRSN (U54CA224068), NIH/NCI R01 CA208756 (to N.H.), Stand Up to Cancer (SU2C) Colorectal Dream Team Translational Research (SU2C-AACR-DT22-17), and the Arthur, Sandra, and Sarah Irving Fund for Gastrointestinal Immuno-Oncology. SU2C is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. Partial clinical trial funding was provided by Novartis. We are also thankful for research fellowships: NIH/NCI T32CA207021, MGH Fund for Medical Discovery, and SITC Forward Fund (to J.H.C.), and DFG, SU2C Peggy Prescott Early Career Scientist Award PA-6146, SU2C Phillip A. Sharp Award SU2C-AACR-PS-32, BroadIgnite, and NIH/NCI K99CA259511 (to K.P.).